3
Announcements
Trials
Browse
Landscape
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Observational
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Lymphoid
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Breast
1
Conditions
Lymphoma
2
Sarcoma
1
Prostatic Neoplasms
1
Pain
1
Ovarian Neoplasms
1
Multiple Myeloma
1
Mixed Dementias
1
Lymphoma, Follicular
1
Lung Neoplasms
1
Lewy Body Disease
1
Kidney Neoplasms
1
Dementia, Vascular
1
Dementia
1
Colorectal Neoplasms
1
Cognitive Dysfunction
1
Breast Neoplasms
1
Interventions
Trastuzumab
243
Paclitaxel
193
Cyclophosphamide
158
Docetaxel
134
Letrozole
113
Capecitabine
113
Fulvestrant
106
Doxorubicin
103
Bevacizumab
87
Carboplatin
81
exemestane
80
Anastrozole
79
Lapatinib
70
Tamoxifen
69
Albumin-Bound Paclitaxel
57
palbociclib
54
pertuzumab
53
Taxes
51
Gemcitabine
50
Radiotherapy
46
eribulin
43
pembrolizumab
41
Everolimus
41
Ado-Trastuzumab Emtansine
41
Vinorelbine
38
130-nm albumin-bound paclitaxel
35
ixabepilone
32
Epirubicin
28
pegfilgrastim
25
liposomal doxorubicin
25
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Breast Neoplasms
×
Referral and Consultation
×
Clear all
NCT02821793
2025-07-01
PRIORITY
Institut Bergonié
Completed
346 enrolled
9 charts